Literature DB >> 25324503

Accurate relapse prediction in ANCA-associated vasculitis-the search for the Holy Grail.

Ulrich Specks1.   

Abstract

Entities:  

Keywords:  ANCA; glomerulonephritis; vasculitis

Mesh：

Year:  2014        PMID： 25324503      PMCID： PMC4341490          DOI： 10.1681/ASN.2014080817

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  19 in total

1.  Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis.

Authors:  Gunnar Tomasson; Peter C Grayson; Alfred D Mahr; Michael Lavalley; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2011-10-29       Impact factor: 7.580

2.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission.

Authors:  Carole Pierrot-Deseilligny Despujol; Jacques Pouchot; Christian Pagnoux; Joël Coste; Loïc Guillevin
Journal:  Rheumatology (Oxford)       Date:  2010-07-31       Impact factor: 7.580

4.  Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  E M Miloslavsky; U Specks; P A Merkel; P Seo; R Spiera; C A Langford; G S Hoffman; C G M Kallenberg; E W St Clair; N K Tchao; L Viviano; L Ding; D Iklé; M Villarreal; B Jepson; P Brunetta; N B Allen; F C Fervenza; D Geetha; K Keogh; E Y Kissin; P A Monach; T Peikert; C Stegeman; S R Ytterberg; J H Stone
Journal:  Arthritis Rheumatol       Date:  2014-11       Impact factor: 10.995

5.  Anticytoplasmic antibodies in Wegener's granulomatosis.

Authors:  F J van der Woude
Journal:  Lancet       Date:  1985-07-06       Impact factor: 79.321

6.  Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?

Authors:  D J Davies; J E Moran; J F Niall; G B Ryan
Journal:  Br Med J (Clin Res Ed)       Date:  1982 Aug 28-Sep 4

7.  Etanercept plus standard therapy for Wegener's granulomatosis.

Authors: 
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

8.  Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis.

Authors:  Javier D Finkielman; Peter A Merkel; Darrell Schroeder; Gary S Hoffman; Robert Spiera; E William St Clair; John C Davis; W Joseph McCune; Andrea K Lears; Steven R Ytterberg; Amber M Hummel; Margaret A Viss; Tobias Peikert; John H Stone; Ulrich Specks
Journal:  Ann Intern Med       Date:  2007-11-06       Impact factor: 25.391

9.  Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.

Authors:  Joanna Robson; Helen Doll; Ravi Suppiah; Oliver Flossmann; Lorraine Harper; Peter Höglund; David Jayne; Alfred Mahr; Kerstin Westman; Raashid Luqmani
Journal:  Ann Rheum Dis       Date:  2013-11-15       Impact factor: 19.103

10.  ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis.

Authors:  Javier D Finkielman; Augustine S Lee; Amber M Hummel; Margaret A Viss; Gregory L Jacob; Henry A Homburger; Tobias Peikert; Gary S Hoffman; Peter A Merkel; Robert Spiera; E William St Clair; John C Davis; W Joseph McCune; Andrea K Tibbs; Steven R Ytterberg; John H Stone; Ulrich Specks
Journal:  Am J Med       Date:  2007-07       Impact factor: 4.965
View more
  8 in total

Review 1.  ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients.

Authors:  Divi Cornec; Emilie Cornec-Le Gall; Fernando C Fervenza; Ulrich Specks
Journal:  Nat Rev Rheumatol       Date:  2016-07-28       Impact factor: 20.543

2.  Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.

Authors:  Lynn A Fussner; Amber M Hummel; Darrell R Schroeder; Francisco Silva; Rodrigo Cartin-Ceba; Melissa R Snyder; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert F Spiera; E William St Clair; Nadia K Tchao; John H Stone; Ulrich Specks
Journal:  Arthritis Rheumatol       Date:  2016-07       Impact factor: 10.995

3.  PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab.

Authors:  Laura S van Dam; Ebru Dirikgil; Edwin W Bredewold; Argho Ray; Jaap A Bakker; Cees van Kooten; Ton J Rabelink; Yoe K Onno Teng
Journal:  Nephrol Dial Transplant       Date:  2021-07-23       Impact factor: 5.992

Review 4.  Central Nervous System Involvement in ANCA-Associated Vasculitis: What Neurologists Need to Know.

Authors:  Yang Zheng; Yinxi Zhang; Mengting Cai; Nanxi Lai; Zhong Chen; Meiping Ding
Journal:  Front Neurol       Date:  2019-01-10       Impact factor: 4.003

5.  Impact of caring for someone with a rare rheumatic condition, views from patients and informal carers-the need for cat-like vigilance.

Authors:  Janice Mooney; Karly Graham; Richard A Watts
Journal:  Rheumatol Adv Pract       Date:  2019-02-01

6.  Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients.

Authors:  Laura S van Dam; Jelle M Oskam; Sylvia W A Kamerling; Eline J Arends; O W Bredewold; Magdalena A Berkowska; Jacques J M van Dongen; Ton J Rabelink; Cees van Kooten; Y K Onno Teng
Journal:  Front Immunol       Date:  2020-12-15       Impact factor: 7.561

7.  Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis.

Authors:  Gwen E Thompson; Lynn A Fussner; Amber M Hummel; Darrell R Schroeder; Francisco Silva; Melissa R Snyder; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert F Spiera; E William St Clair; John H Stone; Ulrich Specks
Journal:  Front Immunol       Date:  2020-09-03       Impact factor: 7.561

8.  Imbalance of Circulatory T Follicular Helper and T Follicular Regulatory Cells in Patients with ANCA-Associated Vasculitis.

Authors:  Ying Xu; Hongmei Xu; Yu Zhen; Xueting Sang; Hao Wu; Cong Hu; Zhanchuan Ma; Miaomiao Yu; Huanfa Yi
Journal:  Mediators Inflamm       Date:  2019-12-02       Impact factor: 4.711
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.